PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Sells $18,542.48 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) CFO Emily Luisa Hill sold 418 shares of the stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $44.36, for a total value of $18,542.48. Following the sale, the chief financial officer now owns 47,086 shares of the company’s stock, valued at $2,088,734.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Emily Luisa Hill also recently made the following trade(s):

• On Monday, January 9th, Emily Luisa Hill sold 758 shares of PTC Therapeutics stock. The stock was sold at an average price of $41.66, for a total value of $31,578.28.

PTC Therapeutics Price Performance

PTCT stock opened at $47.78 on Friday. PTC Therapeutics, Inc. has a twelve month low of $25.01 and a twelve month high of $55.58. The business’s 50-day simple moving average is $39.30 and its 200 day simple moving average is $44.94.

PTC Therapeutics (NASDAQ:PTCT – Get Rating) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.16). The company had revenue of $217.13 million during the quarter, compared to analyst estimates of $194.18 million. As a group, equities research analysts expect that PTC Therapeutics, Inc. will post -6.89 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Credit Suisse Group raised their target price on PTC Therapeutics from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Tuesday, January 10th. Cowen cut their target price on PTC Therapeutics to $44.00 in a report on Tuesday, November 1st. The Goldman Sachs Group assumed coverage on PTC Therapeutics in a report on Wednesday, December 14th. They set a “sell” rating and a $35.00 target price on the stock. Barclays cut their target price on PTC Therapeutics to $47.00 in a report on Tuesday, November 1st. Finally, Morgan Stanley cut their target price on PTC Therapeutics from $54.00 to $40.00 and set an “equal weight” rating on the stock in a report on Friday, October 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $53.73.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PTCT. Raymond James & Associates grew its position in PTC Therapeutics by 17.5% during the first quarter. Raymond James & Associates now owns 8,341 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 1,243 shares in the last quarter. US Bancorp DE boosted its holdings in PTC Therapeutics by 9.9% during the first quarter. US Bancorp DE now owns 9,257 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 832 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in PTC Therapeutics by 53.8% during the first quarter. MetLife Investment Management LLC now owns 38,439 shares of the biopharmaceutical company’s stock valued at $1,434,000 after purchasing an additional 13,448 shares in the last quarter. Sei Investments Co. boosted its holdings in PTC Therapeutics by 2.1% during the first quarter. Sei Investments Co. now owns 44,938 shares of the biopharmaceutical company’s stock valued at $1,677,000 after purchasing an additional 931 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in PTC Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 6,933,076 shares of the biopharmaceutical company’s stock valued at $258,673,000 after purchasing an additional 44,167 shares in the last quarter.

About PTC Therapeutics

(Get Rating)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.